Leerink upgraded Cryoport (CYRX) to Outperform from Market Perform with a price target of $16, up from $10. The firm believes the company is positioned to beat estimates on continued cell and gene therapy market services strength. The analyst is also encouraged by recent stabilization in the company’s MVE business. Leerink sees “beats and raises” well into 2026 for Cryoport.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX: